Today we reported Q1 2024 financial results. Read more about our updates and tune in live to the webcast today at 11:30 AM ET to hear our first quarter highlights: ir.ionispharma.com/news-releases/… $IONS

We're focused on bringing a steady cadence of new medicines to people with serious diseases and believe our long-standing commitment to operating responsibly and sustainably is core to achieving this mission. Learn more: ionispharma.com/about/corporat…

We’re pleased to announce positive topline results from the Phase 1/2a study of our investigational medicine for #AngelmanSyndrome, which we'll independently advance as part of our leading portfolio of medicines for serious neurological diseases. Read more ir.ionispharma.com/news-releases/…

Today, with Biogen, we announced results from the topline Phase 1/2 study of our investigational drug in people living with amyotrophic lateral sclerosis (#ALS). For more information about this program: ir.ionispharma.com/news-releases/…

We look forward to sharing new Phase 3 NEURO-TTRansform subgroup data at the 2024 International Symposium on Amyloidosis (ISA) for our medicine for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Read more: ir.ionispharma.com/news-releases/… $IONS

HCPs: Severely high triglycerides can lead to dangerous consequences. Better understand how to diagnose/manage familial chylomicronemia syndrome #FCS & severe hypertriglyceridemia #sHTG, including dietary restrictions, medications & monitoring procedures: tgaware.com

As part of our commitment to addressing unmet needs for the rare disease community, we’re pleased to share that the European Commission has approved our treatment for amyotrophic lateral sclerosis (#ALS) in adults with a specific gene mutation. Read more: ow.ly/PxfG50S2Uhl

Today we announced positive, Phase 3 data of our investigational medicine for the treatment of hereditary angioedema (#HAE) at the European Academy of Allergy and Clinical Immunology Congress. Read more: ir.ionispharma.com/news-releases/… #EAACIcongress #RareDisease EAACI $IONS

We’re proud to share that NEJM today published the positive Phase 3 OASIS-HAE results for our investigational medicine for the treatment of hereditary angioedema (#HAE), which were simultaneously presented at #EAACIcongress. Read the full article: nejm.org/doi/full/10.10….

Hereditary angioedema (HAE) is a rare, life-threatening genetic condition that involves recurrent attacks of severe swelling. We’re committed to advancing research in this #RareDisease, and shared new Phase 3 data at the #EAACIcongress on our investigational HAE medicine.

#GlobalFattyLiverDay is an annual moment in time to educate about fatty liver disease, which impacts over 115 million people globally and often goes underdiagnosed due to the lack of obvious symptoms. Join us in raising awareness of #FattyLiverDisease. Global Fatty Liver Day

Today, we announced an expanded license agreement with Otsuka Pharmaceutical, under which they will support commercialization in Asia Pacific for our investigational prophylactic medicine for hereditary angioedema (#HAE). Read more: ir.ionis.com/news-releases/… $IONS

The U.S. FDA accepted our New Drug Application for the treatment of familial chylomicronemia syndrome (#FCS) for Priority Review. In addition, enrollment completed in the Ph3 severe hypertriglyceridemia (#sHTG) clinical program: ir.ionis.com/news-releases/… $IONS

We’re pleased to announce that we have achieved full patient enrollment in the pivotal #clinicaltrial of our investigational medicine for people living with #Alexanderdisease. Read more: ir.ionis.com/news-releases/… $IONS

Today we announced positive detailed results from the HALOS study of our investigational medicine for the treatment of #AngelmanSyndrome. Read more: ir.ionis.com/news-releases/… #RareDisease $IONS

We're pleased to share positive results from our HALOS study evaluating our investigational medicine for the treatment of #AngelmanSyndrome. Based on these findings, we believe our Angelman program is positioned to become the cornerstone of our wholly owned pipeline for #neuro.

Today, we shared encouraging results from the HALOS study of our investigational medicine for #AngelmanSyndrome (AS) at the AngelmanSyndromeFdn Family Conference, showing the potentially transformative impact functional improvements could have on people living with AS and their caregivers.

Today we reported Q2 2024 financial results. Read more about our updates and tune in live to the webcast today at 11:30 AM ET to hear our second quarter highlights: ir.ionis.com/news-releases/… $IONS

Save the date for fireside chats with Ionis management at two upcoming investor conferences. Learn more and register: ir.ionis.com/news-releases/… $IONS

Transthyretin amyloidosis (#ATTR) requires timely recognition of symptoms. But accurate diagnosis can take more than 3 years. That’s why increased knowledge about this #RareDisease is critical. Learn more: myattrroadmap.com/about/symptoms…